Alpha 2.0
Login Register
» Authors » Giulia Marchetti

Giulia Marchetti

Explore the profile of Giulia Marchetti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 176
Citations 2777
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Microbiology
Top 10 Co-Authors
Antonella dArminio Monforte
Camilla Tincati
Francesca Bai
Andrea Gori
Andrea Antinori
Alessandro Cozzi-Lepri
Esther Merlini
Matteo Augello
Alessandra Bandera
Valeria Bono
Published In
AIDS
PLoS One
BMC Infect Dis
Antivir Ther
Front Immunol
Affiliations
Soon will be listed here.
Recent Articles
1.
Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: a case series and literature review of real-world data
Lundgren L, Albertini L, De Bona A, Tincati C, Augello M, Marchetti G
JAC Antimicrob Resist . 2025 Mar; 7(2):dlaf032. PMID: 40046068
Background: The POET trial, along with other studies, indicated that switching from IV to partial oral treatment (POT) in selected infective endocarditis (IE) cases is as effective as the traditional...
2.
Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort
Trottier B, Yang C, Watanabe D, Marchetti G, Elbirt D, de Barra E, et al.
HIV Res Clin Pract . 2025 Feb; 26(1):2456890. PMID: 39936702
Background: BICtegravir Single Tablet Regimen (BICSTaR) is an observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV. Objective:...
3.
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV
Taramasso L, Bonora S, Cingolani A, Di Biagio A, Gianotti N, Guaraldi G, et al.
J Antimicrob Chemother . 2025 Jan; 80(3):610-623. PMID: 39888371
Modern ART is evolving, allowing the use of new drug formulations and alternative routes of administration to oral therapy. Long-acting (LA) cabotegravir and rilpivirine, the first fully injectable antiretroviral regimen...
4.
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2
Colaneri M, Canuti M, Torrigiani G, DallOlio L, Bobbio C, Baldi S, et al.
Infect Dis Ther . 2025 Jan; 14(2):447-461. PMID: 39838255
Introduction: Predictors of coronavirus disease 2019 (COVID-19)-related rehospitalization remain underexplored. This study aims to identify the main risk factors associated with rehospitalizations due to severe acute respiratory syndrome coronavirus 2...
5.
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort
Antinori A, Marchetti G, Esposito V, Rusconi S, Canetti D, Quiros-Roldan E, et al.
Int J STD AIDS . 2025 Jan; 36(4):309-318. PMID: 39772928
Background: BICSTaR is a multi-national, observational cohort evaluating the effectiveness, safety, and patient-reported outcomes (PROs) in treatment-naïve (TN) and -experienced (TE) people with HIV-1 receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine...
6.
Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV
Augello M, Bono V, Rovito R, Santoro A, Tincati C, Marchetti G
AIDS . 2024 Oct; 38(14):1987-1990. PMID: 39474654
In this prospective longitudinal study, we evaluated the durability of humoral responses to SARS-CoV-2 mRNA booster vaccination in 93 people with HIV, exploring the possible role of T-cell dysfunction and...
7.
The Omicron Variant Is Associated with a Reduced Risk of the Post COVID-19 Condition and Its Main Phenotypes Compared to the Wild-Type Virus: Results from the EuCARE-POSTCOVID-19 Study
Bai F, Santoro A, Hedberg P, Tavelli A, De Benedittis S, Caporali J, et al.
Viruses . 2024 Sep; 16(9). PMID: 39339976
Post COVID-19 condition (PCC) is defined as ongoing symptoms at ≥1 month after acute COVID-19. We investigated the risk of PCC in an international cohort according to viral variants. We...
8.
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort
Soria A, Graziano F, Ghilardi G, Lapadula G, Dalla Gasperina D, Benatti S, et al.
Heliyon . 2024 Sep; 10(16):e36102. PMID: 39247344
Objective: Monoclonal antibodies (mAbs) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reduced Coronavirus Disease 2019 (COVID-19) hospitalizations in people at risk of clinical worsening. Real-world descriptions are limited. Methods:...
9.
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study
Calcagno A, Cusato J, Cinque P, Marchetti G, Bernasconi D, Trunfio M, et al.
Brain . 2024 Aug; 147(11):3742-3750. PMID: 39171829
It is debated whether CNS involvement begins during acute human immunodeficiency virus (HIV) infection in persons without meningitis/encephalitis and whether specific antiretroviral drugs or combinations would be beneficial. Neurologically asymptomatic...
10.
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study
Kraef C, Tusch E, Singh S, Ostergaard L, Fatkenheuer G, Castagna A, et al.
Lancet Reg Health Eur . 2024 Jul; 44:100989. PMID: 39036304
Background: All-cause and AIDS-mortality in Europe has been decreasing between 1996 and 2020. However, regional differences as well as their drivers remain unclear. This study investigates mortality differences and their...